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Despite the efforts made worldwide to reduce the number of cases of drug-susceptible tuber-
culosis, multidrug-resistant tuberculosis (MDR-TB) constitutes an important public health
issue.  Around 440,000 new cases of MDR-TB are estimated annually, although in 2008 only
7%  of these (29,423 cases) were notiﬁed. The laboratory tests for diagnosing resistance may
be  phenotypic (based on culture growth in the presence of drugs) or genotypic (i.e. identi-
ﬁcation  of the presence of mutations that confer resistance). The urgent need for a rapid
means  of detecting resistance to anti-TB drugs has resulted in the development of many
genotypic  methods over recent years. The treatment of MDR-TB is expensive, complex, pro-
longed  (18–24 months) and associated with a higher incidence of adverse reactions. Some
basic  principles must be observed when prescribing an adequate treatment regimen for
MDR-TB:  (a) the association of at least four drugs (three of which should not have been used
previously);  (b) use of a ﬂuoroquinolone; and (c) use of an injectable anti-TB drug. In Brazil,
the  therapeutic regimen for MDR-TB has been standardized and consists of ﬁve drugs: ter-
izidone, levoﬂoxacin, pyrazinamide, ethambutol and an aminoglycoside (streptomycin or
amikacin). Pulmonary resection is an important tool in the coadjuvant treatment of MDR-
TB.  While a recent meta-analysis revealed an average cure rate of MDR-TB of 69%, clinicalstudies  are currently being conducted with new drugs and with drugs already available on
the  market but with a new indication for TB, with encouraging results that will enable more
effective  treatment regimens to be planned in the future.
Despite the efforts made worldwide to reduce the number
© 2013 Elsevier Editora Ltda.  Este é um artigo Open Access sob a licença de CC BY-NC-NDntroduction
he emergence of drug-resistant tuberculosis (TB) is often
ttributed  to a failure to implement adequate control pro-
rams  for tuberculosis and to appropriately manage cases of
he  disease. Therefore, resistance to TB accurately reﬂects the
∗ Corresponding author at: Associac¸ão  Baiana de Apoio ao Controle da
NUPEP)  – HEOM, Prac¸a  Conselheiro João Alfredo, s/n◦, Pau Miúdo, Salva
E-mail  addresses: acmlemos1@gmail.com, abacontt@ig.com.br (A.C
413-8670     © 2013 Elsevier Editora Ltda. 
ttp://dx.doi.org/10.1016/j.bjid.2013.01.007
Este é um artigo Open Access sob a licençapoor quality of control programs  and is a direct consequence
of  poor therapeutic practices with respect to the use of anti-TB
drugs.1,2 Tuberculose (ABACONTT), Núcleo de Pesquisa em Pneumologia
dor, BA 40320-350, Brazil.
.M. Lemos).
of  cases of drug-susceptible tuberculosis (TB),3 multidrug-
resistant tuberculosis (MDR-TB) constitutes a public health
problem  and represents a severe obstacle to the control of
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Table 1 – Frequency of drug-resistant mutants to anti-TB
drugs.a
Rifampicin 1 drug-resistant mutant for every 107–8 bacilli
Isoniazid 1 drug-resistant mutant for every 105–6 bacilli
Ethambutol 1 drug-resistant mutant for every 105–6 bacilli
Pyrazinamide 1 drug-resistant mutant for every 102–4 bacilli
Streptomycin 1 drug-resistant mutant for every 105–6 bacilli
Ethionamide 1 drug-resistant mutant for every 103–6 bacilli
a Adapted from Canetti et al. Advances in techniques of testing
mycobacterial drug sensitivity, and the use of sensitivity tests in
tuberculosis control programmes.85240  b r a z j i n f e c t d 
TB, particularly in countries in which the prevalence of this
disease  remains high.4 Over the past two decades, various
publications have registered the emergence of MDR-TB world-
wide.  MDR-TB is deﬁned as cases of tuberculosis that are
resistant  to at least rifampicin and isoniazid.5–8
In 2008, 29,423 new cases of MDR-TB were notiﬁed world-
wide  in the 127 countries in which at least one case of this
form  of the disease was  reported to the World Health Organi-
zation  (WHO). These ﬁgures account for only 7% of the 440,000
new  cases of MDR-TB estimated for that year and, of these,
only  one-ﬁfth (1.2% of the total number) was  treated in accor-
dance  with the WHO  recommendations. Around 50% of the
global  burden of MDR-TB is concentrated in two countries,
India  and China, followed by Russia (9%). The WHO  estimates
that  around 150,000 deaths occurred in patients with MDR-
TB  in 2008.9 The difference between the number of estimated
cases  and the number of treated cases should be interpreted as
potential disseminating sources of multidrug-resistant strains
and  may  be responsible for the increase in the number of
cases.
More  recently, cases have been described of extensively
drug-resistant tuberculosis (XDR-TB) in which Mycobacterium
tuberculosis is resistant to rifampicin, isoniazid, a ﬂuoro-
quinolone and a second-line injectable drug (capreomycin,
kanamycin or amikacin). An epidemic of XDR-TB was
described for the ﬁrst time in KwaZulu-Natal in South Africa
in  a population of HIV/AIDS patients, where the mean sur-
vival  time between diagnosis by sputum smear microscopy
and  death was  16 days.10
According to a recent document issued by the WHO,  963
cases  of XDR-TB were  reported in 2008 worldwide, these data
referring  to all of the 41 countries in which at least one case
was  notiﬁed.9 Only 6 of these 41 countries (15%) reported
more  than 10 cases of XDR-TB. The proportion of cases of
MDR-TB  that are in fact XDR-TB exceeds 10% in the following
countries: Estonia (19.7%), Latvia (15.1%), South Africa (10.5%)
and  Tajikistan (21%).11 Nevertheless, considering the difﬁculty
in  performing susceptibility tests for second-line drugs in rou-
tine  services in the majority of countries, these data are in fact
underestimated.
The  worldwide trend of anti-TB drug resistance can be
estimated for only 59 countries in which more  than one inves-
tigation  of resistance was  performed between 1994 and 2009.9
Over the last decade in Brazil, an increase has occurred in pri-
mary  isoniazid (H)-resistance from 4.4% (Nationwide Survey
into  Anti-TB Drug Resistance, 1995–97) to 6%, with an increase
in  rifampicin (R)-resistance from 1.3% to 1.5%. With respect to
MDR-TB, a slight increase was  found, from 1.1% at the ﬁrst
survey  to 1.4% at the second.12
Resistance  to  anti-TB  drugs
Resistance to anti-TB drugs is the result of spontaneous muta-
tions  in the genome of M. tuberculosis and not the result of
horizontal  gene transfer.13 The mutations that produce resis-
tance  occur at rates that are predictable for each drug, as
shown  in Table 1. So, for example, the occurrence of a mutant
microorganism resistant to H occurs for every 105 or 106 bacilli
and  a mutant resistant to R for every 107 or 108 bacilli. Themutation of M.  tuberculosis occurs independently for each one
of  the drugs; hence the possibility of the occurrence of asso-
ciated  resistance is equal to the product of their respective
resistance rates. Therefore, for a mutant to appear that is
naturally  and simultaneously resistant to both R and H, the-
oretically  a population of 1012 or 1014 microorganisms would
be  necessary, making the possibility that it would lodge in the
human  body highly unlikely.1
With selection, particularly as a result of inappropriate
treatment management, drug-resistant organisms multiply
and  become dominant. Once created, drug-resistant strains
may  be transmitted to individuals who were not previ-
ously  exposed to anti-TB drugs (primary resistance).14,15 The
types  of resistance to M.  tuberculosis may  be summarized as
follows:16
• Natural resistance: resulting from natural mutation irre-
spective  of previous drug exposure and directly proportional
to  the number of mutant bacilli;
• Primary resistance: cases of resistance in individuals known
not  to have been previously exposed to anti-TB drugs;
•  Acquired resistance: cases of resistance in which patients
were  previously submitted to TB treatment, generally inad-
equately.
Resistance  to H is more  often due to a mutation in the
katG  gene that codiﬁes the katG enzyme, a catalase-peroxidase
enzyme. Studies conducted by Zhang et al. at the beginning of
the  1990s showed that H is, in fact, a pro-drug that is activated
by  the katG enzyme.17,18 A later study conducted by Heym
et  al. identiﬁed the katG gene in the chromosome of various
mycobacteria including M. tuberculosis and, in addition, these
investigators studied the mutations that affect this gene in the
isolates  of clinical specimens that are H-resistant.19 A great
number  of reports indicate that mutations in the katG enzyme
are  responsible for around 60% of cases of isoniazid-resistant
strains isolated from patients.19–25 Nevertheless, some muta-
tions  in other genes have been identiﬁed in isoniazid-resistant
strains, including the inhA gene, which codiﬁes the enzyme of
mycolic  acid involved in the formation of the M. tuberculosis
cell  wall, and the ahpC gene that codiﬁes alkyl hydroperoxi-
dase, among others.23,26,27 A study carried out in Brazil using
isoniazid-resistant strains (n = 69) from three states (Rio de
Janeiro,  São Paulo and Rio Grande do Sul) revealed a predom-
inance  of the katG gene mutation, although other mutations
(in  the inhA and ahpC genes) have also been identiﬁed.23
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Rifampicin inhibits the beta subunit of the RNA poly-
erase. The rpoB gene codiﬁes this enzyme and was  initially
dentiﬁed in Escherichia coli and Mycobacterium leprae and, later,
n  M.  tuberculosis.28 The rpoB gene mutations are identiﬁed in
0–98%  of rifampicin-resistant strains. With the advances in
olecular  biology techniques, the fragment sequencing of the
poB  gene has proven to constitute a rapid way  of detecting
-resistance, substituting the slower classic method (the pro-
ortion  method) that is used routinely in most services.29,30
In recent decades, knowledge on the genetic mechanisms
f  M.  tuberculosis resistance to anti-TB drugs has grown, and
his  has also facilitated the development of more  accurate
nd  faster techniques for detecting resistance.31–40 Neverthe-
ess,  the limited availability of laboratories with the capacity to
outinely offer these new techniques of diagnosing resistance
epresents an impediment to their wider use in countries in
hich  the burden of this disease is high.
iagnosis  of  resistance  to  anti-TB  drugs
aboratory methods of diagnosing resistance to anti-TB drugs
ay  be classiﬁed as phenotypic (based on culture growth in
he  presence of drugs) or genotypic (i.e. identiﬁcation of the
resence  of mutations that confer resistance).
henotypic  methods
henotypic methods, also referred to as drug susceptibility
ests, can be performed in solid or liquid media. The suscepti-
ility  tests used in solid media cultures (Lowenstein–Jensen
nd Ogawa–Kudoh) are: (a) the proportion method, (b) the
bsolute  concentration method, and (c) the resistance ratio
ethod.  The classic proportion method is the most commonly
sed  both worldwide and in Brazil. One of the limitations of
he  drug susceptibility tests performed in solid media is the
elay,  as these tests generally require around two months for
esults to be released.
Liquid  medium, using the BACTEC MGIT 960 system, signif-
cantly  reduces the time involved in detecting M. tuberculosis
o  two weeks and after 1–2 weeks the results of the suscepti-
ility  test are available.2 The sensitivity and speciﬁcity of the
GIT  960 system (96% and 94.6%, respectively) are similar to
hose found with the proportion method, and this technique
as  already been validated for use in Brazil.41 The greatest dis-
dvantage  of the liquid medium technique is its high cost.2
he accuracy of susceptibility testing varies in accordance
ith the drug tested, accuracy being greater in the case of
ifampicin  and isoniazid and poorer in the case of ethambutol
nd  streptomycin.2
enotypic  methods
he genotypic methods, also referred to as molecular meth-
ds,  are based on the detection of the mutations that confer
esistance to anti-TB drugs. Many  genotypic methods have
een  developed over recent years in response to the urgent
eed  to be able to detect resistance to anti-TB drugs rapidly.
he  molecular tests most commonly used worldwide are the
enoType  MTBDRplus, the INNO-LiPA Rif.TB, and the Xpert3;1  7(2):239–246  241
MTB/RIF  assays. The GenoType MTBDRplus assay (Hain Life-
science)  detects mutations in the katG, inhA and rpoB genes,
identifying R- and H-resistance. The sensitivity and speciﬁcity
of  the method for the detection of R-resistance are 98% and
99%,  respectively, while for the detection of H-resistance, sen-
sitivity  is 85% and speciﬁcity 99%.42 The INNO-LiPA Rif.TB
assay  (sensitivity 97%, speciﬁcity 99%) detects R-resistance by
detecting the rpoB gene mutation.42 Finally, the Xpert MTB/RIF
assay  identiﬁes R-resistance, with results being available in
around two hours and without any need for a sophisticated
laboratory infrastructure, allowing the test to be performed at
the site where the patient is receiving care. The reported sen-
sitivity  for a diagnosis of TB using the Xpert MTB/RIF assay
varies  according to the study, ranging from 70% to 100% in
cases  of positive culture and around 60% in cases of TB in
which  culture is negative. The speciﬁcity of the method ranges
from  91% to 100%. For the detection of R-resistance, sensitivity
and  speciﬁcity are 98% and 99%, respectively.32–40,43
Despite the promising perspective of the use of molecular
tests, also known as rapid molecular testing, for the diagnosis
of  resistance, the WHO  has warned that these tests need to
be  validated in the countries in which they are to be used,
since  the frequency of the mutations may  vary in accordance
with  the region.32 In Brazil, validation studies of these new
rapid  tests for the diagnosis of resistance are currently being
conducted  and may  constitute an important step toward their
future  use in this country.
In  Brazil, the classic proportion method has been the
technique most commonly used in the healthcare network;
however, the new methods are already available in some ref-
erence  centers. Increasing access to these new methods for
the  rapid detection of resistance in routine conditions should
constitute  an important challenge for the National Program
for  the Control of Tuberculosis (PNCT).
The  treatment  of  MDR-TB
MDR-TB is both costly and complex to treat, since second-
line  drugs are required that are associated with a higher
incidence of adverse reactions.44,45 In addition, treatment is
more  prolonged compared to when ﬁrst-line drug regimens
are  used. The accumulated evidence of MDR-TB treatment
outcome remains tenuous and is based on observational stud-
ies  and expert opinions. The lack of uniformity with respect
to  the drugs and regimens used (duration of treatment, super-
vised  administration versus self-administration), represents
an  important obstacle when comparing the different stud-
ies.  Nevertheless, some publications have indicated that the
organization  of the healthcare services and the use of super-
vised  treatment are factors that contribute toward increasing
success  rates.46–48 In addition, mathematical models have
suggested that this treatment may  be cost-effective, even in
countries with limited ﬁnancial resources.49
The control of resistant TB, particularly in cases of MDR-TB
and  XDR-TB, represents an important challenge that has to
be  confronted. Efforts must be made to improve management
of  these cases, focusing particularly on identifying new drugs
that  would permit shorter, more  effective treatment regimens
to  be implemented in cases of MDR-TB and XDR-TB.50,51
i s . 2 0242  b r a z j i n f e c t d 
The ideal treatment for MDR-TB, deﬁned as TB that is
simultaneously R- and H-resistant (associated or not with
resistance  to other ﬁrst-line drugs), remains a challenge that
has  to be confronted within the context of current knowledge.
The  principal difﬁculties include: the high cost of treatment,
its  relatively poor efﬁcacy, the side effects of the available
drugs and the prolonged duration of treatment. A recent meta-
analysis  based on retrospective cohort studies on MDR-TB
treatment outcome showed a mean success rate of 69% and,
furthermore, the superiority of supervised treatment regi-
mens  of at least 18 months’ duration.52
Some basic principles must be observed when planning
an  adequate treatment regimen for MDR-TB: (1) the associa-
tion  of at least four drugs proven to have antimycobacterial
efﬁcacy, three of which should not have previously been
used  by the patient; (2) use of a ﬂuoroquinolone with anti-
TB  activity (oﬂoxacin, levoﬂoxacin or moxiﬂoxacin); (3) use
of  an injectable drug (streptomycin, amikacin, kanamycin or
capreomycin); and (4) prolonged, supervised treatment (18–24
months)  carried out in a tertiary referral unit.53
Prior to 1995 in Brazil, some experiences were initi-
ated in reference centers in São Paulo, Rio de Janeiro and
Porto  Alegre in an attempt to elaborate MDR-TB treatment
regimens, and between 1995 and 1998 a multicenter proto-
col  was  implemented.54 In 2000, the Brazilian Ministry of
Health  considered the standardized 18-month, 5-drug reg-
imen  (amikacin, clofazimine, terizidone, ethambutol and
oﬂoxacin)  as validated and adopted it for use in this coun-
try.  The MDR-TB epidemiological surveillance system was also
implemented in that year, with further improvements being
included  in 2004.
The  modiﬁcations introduced by the Brazilian Ministry
of  Health’s National Program for the Control of Tuberculosis
(PNCT) in 2009 with respect to the treatment of MDR-TB were:
(a)  to substitute the ﬂuoroquinolone oﬂoxacin for high-dose
levoﬂoxacin; and (b) to promote the use of streptomycin (S)
rather  than amikacin (AM), although the use of AM is still
recommended in two situations: (1) for patients who have
already  used S in previous treatments; and (2) in cases of
proven  in vitro resistance to streptomycin.55 In relation to the
ﬂuoroquinolone, the decision was  made to use high-dose levo-
ﬂoxacin  for two reasons: (a) few studies had been conducted
on  the prolonged use of moxiﬂoxacin and (b) there was  evi-
dence  suggesting this drug as a future alternative for reducing
the  duration of treatment in treatment-naïve patients.56
Therefore, the treatment regimen currently used for MDR-
TB  in Brazil consists of ﬁve drugs in the intensive phase
(streptomycin, ethambutol, levoﬂoxacin, pyrazinamide and
terizidone)  and three in the maintenance phase (ethambutol,
levoﬂoxacin and terizidone), as described in Table 2. Strepto-
mycin  or amikacin is used for ﬁve days a week in the ﬁrst two
months  and then three times a week for the next four months.
The  duration of the MDR-TB treatment regimen is 18–24
months and treatment administration should be supervised
in  the reference unit where the patient is being treated or in
the  basic healthcare unit closest to the patient’s home (shared
55supervision).
According to the MDR-TB data system, 6136 cases were
notiﬁed in Brazil between January 1992 and June 2012. The
cohort  analysis of the treatment outcomes of patients entering 1 3;1 7(2):239–246
the  system between January 1992 and December 2010 showed
a  mean success rate of 60.6%, although there were  regional
differences between states attributed to factors such as the
organization of the healthcare service, the presence of comor-
bidities  and a delay in detecting cases of resistance.57
Treatment  of  extensively  drug-resistant
tuberculosis (XDR-TB)
Extensively drug-resistant tuberculosis (XDR-TB), deﬁned as
TB that is resistant to R, H, a ﬂuoroquinolone and a second-
line  injectable drug (amikacin, kanamycin or capreomycin),
represents a serious public health issue in some regions of
the  world today. Studies evaluating the treatment of XDR-TB
have,  in general, shown disappointing results, with poor suc-
cess  rates,58,59 although a study conducted in Peru with a small
number  of patients reported a cure rate of 60%.60 A recent, ret-
rospective  cohort study (n = 174) conducted in South Africa in a
population with an elevated TB/HIV co-infection rate, showed
an  early mortality rate of 32% and identiﬁed the following
independent factors as being responsible for reducing the
number  of deaths: the use of moxiﬂoxacin in the therapeutic
scheme and a regimen containing a greater number of drugs.
On  the other hand, the presence of a pretreatment culture with
proven  multidrug-resistance was  found to be a factor indica-
tive  of poorer prognosis.61 More recent studies have indicated
the  importance of linezolid, an oxazolidinone, in association
with  other anti-TB drugs in individualized regimens. Never-
theless,  the high cost of this drug and the development of
severe  adverse effects such as myelosuppression and periph-
eral  neuropathy constitute important obstacles to its use in
the  majority of tertiary TB management centers.62–70
In summary, there is still no consensus on the most
appropriate treatment regimen for XDR-TB. Ongoing research
studies  with new drugs may  show promise in the future
and  may  permit more  rational treatment regimens for these
patients.50,51 Cases of XDR-TB should be monitored in a ter-
tiary  reference center, with individualized treatment regimens
consisting  of combinations of reserve drugs.9
Adjuvant  surgical  treatment  of  MDR-TB  and
XDR-TB
Particularly in MDR-TB, a negative sputum smear or a signiﬁ-
cant  reduction in the bacillary load is desirable prior to surgery
in  order to minimize the incidence of recurrences, bron-
chopleural ﬁstula and postoperative empyema. The principal
indications for the adjuvant surgical treatment of MDR-TB
are:  (a) persistently positive sputum despite optimized treat-
ment;  (b) localized disease, cavitary pulmonary tuberculosis
with  a high risk of recurrence and cavities with no signs of
regression  during treatment, and in cases of unilateral lung
destruction; (c) proﬁle of resistance to at least four drugs;
(d)  multiple recurrences; (e) repeated hemoptysis and/or sec-
71–78ondary  infections.
The presence of a cavitary lesion reinforces the need for
early  surgery in view of the difﬁculty of drug penetration
and the greater population of bacilli. The drugs should be
b r a z j i n f e c t d i s . 2 0 1 3;1  7(2):239–246  243
Table 2 – Treatment regimens for multidrug-resistant tuberculosis (MDR-TB).
Regimen Drug Doses per weight range Months
≤20 kg 21–35 kg 36–50 kg >50 kg
2S5ELTZ
Intensive phase
1st  stage
Streptomycin 20 mg/kg 500 mg/day 750–1000 mg/day 1000 mg/day
2
Ethambutol 25 mg/kg 400–800 mg/day 800–1200 mg/day 1200 mg/day
Levoﬂoxacin 10 mg/kg 250–500 mg/day 500–750 mg/day 750–1000 mg/day
Pyrazinamide 35  mg/kg 1000  mg/day 1500  mg/day 1500 mg/day
Terizidone 20  mg/kg 500  mg/day 750 mg/day 750 mg/day
4S3ELTZ
Intensive phase
2nd  stage
Streptomycin 20 mg/kg 500 mg/day 750–1000 mg/kg 1000 mg/day
4
Ethambutol 25 mg/kg 400–800 mg/day 800–1200 mg/day 1200 mg/day
Levoﬂoxacin 10 mg/kg 250–500 mg/day 500–750 mg/day 750–1000 mg/day
Pyrazinamide 35 mg/kg 1000 mg/day 1500 mg/day 1500 mg/day
Terizidone 20 mg/kg 500 mg/day 750 mg/day 750 mg/day
12ELT
Maintenance phase
Ethambutol 25  mg/kg 400–800 mg/day 400–800 mg/day 1200 mg/day
12Levoﬂoxacin 10 mg/kg 250–500 mg/day 500–750 mg/day 750–1000 mg/day
Terizidone 20 mg/kg 500 mg/day 750 mg/day 750 mg/day
The number preceding the abbreviation indicates the number of months of treatment. The subscript number after the letter indicates the
ed. S
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mnumber of days per week on which the drug has to be administer
terizidone.
aintained for a prolonged period following surgery (18–24
onths).  The most recent studies conducted with a more  care-
ul  selection of patients show better results with respect to
ortality  rates, complications and recurrences.74–76
Although few studies have been published, the indications
f  surgery as adjuvant therapy in cases of XDR-TB are similar
o  those for MDR-TB: patients with a localized lesion and lack
f  an initial response to treatment.75,76,78
ew  drugs  for  the  treatment  of  TBhe development and validation of new drugs for the treat-
ent  of TB are necessary to allow more  appropriate treatment
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regimens  to be elaborated, focusing on the following objec-
tives:  (a) shortening the treatment time in cases of TB and
of  latent TB infection (LTBI); (b) reducing drug interaction with
antiretroviral drugs; and c) identifying more  effective and safer
therapeutic  options for MDR-TB and XDR-TB.55
Some new drugs and others already established on the
market  for other indications are currently being evaluated in
clinical trials for TB treatment. Fig. 1 shows some of the drugs
that  appear promising for future use in TB.79,81 At present, two
new  drugs are showing results promising in clinical trials for
treatment  of MDR-TB: bedaquiline (TMC 207) and delamanid
(OPC  67683). In December 2012, bedaquiline, a diarylquinoline
with a novel mode of action speciﬁcally inhibiting mycobacte-
rial  ATP synthase, received approval from the Food and Drug
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Administration (FDA) for the treatment of pulmonary MDR-TB
as  part of combination therapy in adults.82,83 In its turn, dela-
manid,  a new nitroimidazole derivative, that inhibits mycolic
acid  synthesis, was  associated with an increase in sputum
conversion at 2 months among patients with MDR-TB (45.4%
as  compared with 29.6% of patients who  received a back-
ground  drug regimen plus placebo).84
Conclusions
In view of the epidemiological context of tuberculosis, partic-
ularly  in countries with a high burden of the disease, the use of
more  rapid methods for diagnosing the disease and molecular
resistance tests, particularly R- and H-resistance, is urgently
required.  Furthermore, new drugs need to be developed for the
treatment  of MDR-TB and XDR-TB.
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